Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma.
Khushman M, Patel GK, Laurini JA, Bhardwaj A, Roveda K, Donnell R, Sherling K, Case B, Frankel AE, Pai S, Taylor W, Tan MCB, Mizrahi M, Nelson C, Wyatt M, Patton M, McClellan S, Singh S, Wang B, Singh AP. Khushman M, et al. Among authors: taylor w. J Gastrointest Oncol. 2019 Aug;10(4):695-702. doi: 10.21037/jgo.2018.07.02. J Gastrointest Oncol. 2019. PMID: 31392050 Free PMC article.
Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines.
Khushman M, Patel GK, Hosein PJ, Laurini JA, Cameron D, Clarkson DR, Butler TW, Norden CW, Baliem W, Jones V, Bhadkamkar S, Nelson C, Lee F, Singh AP, Taylor WR. Khushman M, et al. Among authors: taylor wr. J Gastrointest Oncol. 2018 Jun;9(3):416-424. doi: 10.21037/jgo.2018.02.03. J Gastrointest Oncol. 2018. PMID: 29998006 Free PMC article.
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS, McMillin GA, Patel GK, Awan S, Taylor WR, Pai S, Frankel AE, Nelson C, Wang B, Hosein PJ, Singh AP, Khushman M. Maharjan AS, et al. Clin Colorectal Cancer. 2019 Sep;18(3):e280-e286. doi: 10.1016/j.clcc.2019.04.005. Epub 2019 May 3. Clin Colorectal Cancer. 2019. PMID: 31160238
Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.
Patel GK, Perry JB, Abdul-Rahim O, Frankel AE, Cameron D, Taylor W, Rocconi RP, Abushahin L, Nelson C, Singh AP, Khushman M. Patel GK, et al. Among authors: taylor w. J Cancer Res Ther. 2020 Jul-Sep;16(4):950-954. doi: 10.4103/jcrt.JCRT_729_18. J Cancer Res Ther. 2020. PMID: 32930150 Free article. Review.
4,193 results